ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
September 19 2017 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci,
Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of
Research and Development and Chief Medical Officer, will present at
the Cantor Fitzgerald Global Healthcare Conference on September
26th, 2017, at 10:20 a.m. ET at the InterContinental New York
Barclay Hotel in New York, New York.
You can access the live webcast of the presentation via the
“Investors & Media” section of our website, www.arqule.com,
under “Events & Presentations.” A replay of the webcast will be
available shortly after the conclusion of the presentation.
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of five drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s proprietary pipeline includes: ARQ
087, a multi-kinase inhibitor designed to preferentially inhibit
the fibroblast growth factor receptor (FGFR) family, in phase 2 for
iCCA and in phase 1b for multiple oncology indications; ARQ 092, a
selective inhibitor of the AKT serine/threonine kinase, in a phase
1/2 company sponsored study for Overgrowth Diseases, in a phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), as well as in multiple oncology
indications; ARQ 751, a next generation AKT inhibitor, in phase 1
for patients with AKT1 and PI3K mutations; and ARQ 761, a
β-lapachone analog being evaluated as a promoter of NQO1-mediated
programmed cancer cell necrosis, in phase 1/2 in multiple oncology
indications in partnership with the University of Texas
Southwestern Medical Center. In addition, we have advanced ARQ 531,
an investigational, orally bioavailable, potent and reversible
inhibitor of both wild type and C481S-mutant BTK, in phase 1 for
patients with B-cell malignancies refractory to other therapeutic
options. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds. You can
follow us on Twitter and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170919005168/en/
ArQuleDawn Schottlandt, 781-994-0300Vice President, Investor
Relations/ Corp. Communicationswww.arqule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024